Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to announce the launch of the new Oxford Centre for Neuroinflammation (OCNI), which aims to shed light on the causes of neurodegenerative diseases and uncover new treatment pathways.

Lars Fugger © John Cairns

Headed by Professor Lars Fugger, the centre will bring together biomedical, analytical and clinical expertise, to investigate the neuroinflammatory mechanisms that underpin a range of neurodegenerative diseases. This will allow our researchers to develop new tools for faster diagnosis, more accurate prognosis and new targets for life-changing and life-saving treatments.

We hope that the opening of the OCNI will help accelerate our understanding of neurodegenerative diseases and thus pave the way for novel treatments for patients worldwide. - Professor Lars Fugger

As part of the Nuffield Department of Clinical Neurosciences, the OCNI will be based in the MRC Weatherall Institute of Molecular Medicine at the John Radcliffe Hospital. Within this rich multidisciplinary context the OCNI will capitalise on recent technological advances, including cutting edge experimental platforms, genetic microsurgery techniques and single-cell analysis methods, as well as on the on-going ‘big data’ explosion, which is enabling access to genetic, clinical and epidemiological information from hundreds of thousands of patients.

OCNI_ImageCopy.jpegBy combining cutting-edge scientific approaches with clinically relevant data sets and with direct access to patient samples, the OCNI will be uniquely placed to drive forward medical research, interrogating the neuroinflammatory basis of neurodegenerative diseases.

Funded by the Oak Foundation and private donors the centre will ensure that new findings within the field are translated back to real progress in the clinic. The centre will focus on four major goals:

  1. Understanding how genetic information can be harnessed to help facilitate diagnosis
  2. Investigating the interplay between environmental factors and disease
  3. Establishing how to predicted drug efficacy
  4. Ascertaining whether drugs already tested and approved can be re-purposed for the treatment of neurodegenerative disease.

By addressing these questions, the centre will help to provide life changing therapeutic options to enable patients worldwide to live active and fulfilling lives. 

Find out more 

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'

Discovery of gene involved in chronic pain creates new treatment target

Our researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord. This is helping them to understand an important mechanism underlying chronic pain in humans, and provides a new treatment target.